Recently, the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) Omicron
variant (B. 1.1. 529) was first identified in Botswana in November 2021. It was first reported …

The past several months have witnessed the emergence of SARS-CoV-2 variants with novel
spike protein mutations that are influencing the epidemiological and clinical aspects of the …

Abstract SARS-CoV-2 Omicron subvariants BA. 2.12. 1 and BA. 4/5 have surged notably to
become dominant in the United States and South Africa, respectively,. These new …

The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2), has resulted in millions of deaths and threatens …

Summary Recently emerged SARS-CoV-2 Omicron subvariant, BA. 2.75, displayed a growth
advantage over circulating BA. 2.38, BA. 2.76, and BA. 5 in India. However, the underlying …

Two and a half years into the COVID-19 pandemic, we have gained many insights into the
human antibody response to the causative SARS-CoV-2 virus. In this Review, we …

Host–pathogen interactions and pathogen evolution are underpinned by protein–protein
interactions between viral and host proteins. An understanding of how viral variants affect …

Neutralizing antibodies (nAbs) elicited against the receptor binding site (RBS) of the spike
protein of wild-type severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are …

SARS-CoV-2 Omicron is highly transmissible and has substantial resistance to
neutralization following immunization with ancestral spike-matched vaccines. It is unclear …

The rapid spread of the highly contagious Omicron variant of severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) along with its high number of mutations in the spike …